Proton pump inhibitors are not associated with fundic gland polyps - a systematic review that takes into consideration all known confounders.
Journal
European journal of gastroenterology & hepatology
ISSN: 1473-5687
Titre abrégé: Eur J Gastroenterol Hepatol
Pays: England
ID NLM: 9000874
Informations de publication
Date de publication:
01 Jul 2024
01 Jul 2024
Historique:
medline:
3
6
2024
pubmed:
3
6
2024
entrez:
3
6
2024
Statut:
ppublish
Résumé
Sporadic fundic gland polyps (FGPs) progress, albeit rarely, to dysplasia and cancer. Two meta-analyses, including 8 and 11 studies, concluded that proton pump inhibitors (PPIs) were associated with FGPs. Intervention is considered unnecessary when FGPs have a background of PPIs use. Both meta-analyses, however, disregarded known confounders: age, sex, endoscopy indications, study design (prospective or retrospective), duration of PPI use, and H. pylori infection. Confounders are known to invalidate meta-analyses. We followed PRIXMA guidelines and searched the literature for studies on FGPs in PPI-users and PPI-nonusers. In the 22 studies searched, we compared FGPs in PPI-users (n = 6534) and PPI-nonusers (n = 41 115). Heterogeneity was significant (Cochran Q = 277.8, P < 0.0001; I2 = 92.8%), annulling meta-analysis performed by blanket tallying. To offset the above confounders, we matched PPI-users and PPI-nonusers by (a) age and sex (n = 4300 and 29 307, respectively) and (b) their propensity scores derived from the confounders (n = 2950 and 4729, respectively). After both matching, FGPs were not significantly different between PPI-users and PPI-nonusers [odds ratio (OR) = 1.1, P = 0.3078; OR = 0.9, P = 0.3258, respectively]. Furthermore, FGP frequency did not correlate with increasing duration of PPI use (Pearson and Spearman correlation coefficients = 0.1162, 0.0386, P < 0.6064, 0.8646, respectively); it was not significantly different between any of the duration periods of observation, namely, <10, 10-20, 20-40, >40 months, nor was it significantly different between PPI-users and PPI-nonusers within each duration period (P > 0.05). We conclude that PPIs are not associated with FGPs, implying that a background history of PPI use is not a justification for nonintervention in the management of FGPs.
Identifiants
pubmed: 38829941
doi: 10.1097/MEG.0000000000002788
pii: 00042737-202407000-00002
doi:
Substances chimiques
Proton Pump Inhibitors
0
Types de publication
Journal Article
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
831-844Informations de copyright
Copyright © 2024 The Author(s). Published by Wolters Kluwer Health, Inc.
Références
Luo H, Fan Q, Xiao S, Chen K. Changes in proton pump inhibitor prescribing trend over the past decade and pharmacists’ effect on prescribing practice at a tertiary hospital. BMC Health Serv Res 2018; 18:537.
Zeng W, Finlayson AE, Shankar S, de Bruyn W, Godman B. Prescribing efficiency of proton pump inhibitors in China: influence and future directions. BMC Health Serv Res 2015; 15:11.
Yamamichi N, Shimamoto T, Takahashi Y, Takahashi M, Takeuchi C, Wada R, et al. Trends in proton pump inhibitor use, reflux esophagitis, and various upper gastrointestinal symptoms from 2010 to 2019 in Japan. PLoS One 2022; 17:e0270252.
Mazer-Amirshahi M, Mullins PM, van den Anker J, Meltzer A, Pines JM. Rising rates of proton pump inhibitor prescribing in US emergency departments. Am J Emerg Med 2014; 32:618–622.
National Health Service (NHS Digital). Prescription cost analysis - England, 2017 [PAS]. 2018. https://digital.nhs.uk/data-andinformation/publications/statistical/prescription-cost-analysis/prescription-cost-analysis-england-2017. [Accessed 21 June 2018]
Hálfdánarson OO, Pottegård A, Björnsson ES, Lund SH, Ogmundsdottir MH, Steingrímsson E, et al. Proton-pump inhibitors among adults: a nationwide drug-utilization study. Therap Adv Gastroenterol 2018; 11:1756284818777943.
Torres-Bondia F, de Batlle J, Galván L, Buti M, Barbé F, Piñol-Ripoll G. Evolution of the consumption trend of proton pump inhibitors in the Lleida Health Region between 2002 and 2015. BMC Public Health 2022; 22:818.
Lassalle M, Le Tri T, Bardou M, Biour M, Kirchgesner J, Rouby F, et al. Use of proton pump inhibitors in adults in France: a nationwide drug utilization study. Eur J Clin Pharmacol 2020; 76:449–457.
Shanika LGT, Reynolds A, Pattison S, Braund R. Proton pump inhibitor use: systematic review of global trends and practices. Eur J Clin Pharmacol 2023; 79:1159–1172.
Thomson AB, Sauve MD, Kassam N, Kamitakahara H. Safety of the long-term use of proton pump inhibitors. World J Gastroenterol 2010; 16:2323–2330.
Lehault WB, Hughes DM. Review of the long-term effects of proton pump inhibitors. Fed Pract 2017; 34:19–23.
Haastrup PF, Thompson W, Søndergaard J, Jarbøl DE. Side effects of long-term proton pump inhibitor use: a review. Basic Clin Pharmacol Toxicol 2018; 123:114–121.
Koyyada A. Long-term use of proton pump inhibitors as a risk factor for various adverse manifestations. Therapie 2021; 76:13–21.
Graham JR. Gastric polyposis: onset during long term therapy with omeprazole. Med J Aust 1992; 157:287–288.
Choudhry U, Boyce HW Jr, Coppola D. Proton pump inhibitor associated gastric polyps: a retrospective analysis of their frequency, and endoscopic, histologic, and ultrastructural characteristics. Am J Clin Pathol 1998; 110:615–621.
Reekmans A, Serge N, Reynaert H, Urbain D. Fundic gland polyps and chronic PPI treatment. Gastroenterology 2001; 120 (Suppl 1):A244.
Jalving M, Koornstra JJ, Wesseling J, Boezen HM, De Jong S, Kleibeuker JH. Increased risk of fundic gland polyps during long-term proton pump inhibitor therapy. Aliment Pharmacol Ther 2006; 24:1341–1348.
Ally MR, Veerappan GR, Maydonovitch CL, Duncan TJ, Perry JL, Osgard EM, et al. Chronic proton pump inhibitor therapy associated with increased development of fundic gland polyps. Dig Dis Sci 2009; 54:2617–2622.
Hsu WH, Wu IC, Kuo CH, Su YC, Lu CY, Kuo FC, et al. Influence of proton pump inhibitor use in gastrointestinal polyps. Kaohsiung J Med Sci 2010; 26:76–83.
Yoshida N, Yamada S, Fukumoto K, Omatsu T, Yagi N, Takagi T, et al. W1083 the development of fundic gland polyps associated with chronic proton pump inhibitor therapy involves in increased expression of Aquaporin 4. Gastroenterology 2010; 138:S–648.
Zelter A, Fernandez JL, Bilder C, Rodriguez P, Wonaga A, Dorado F, et al. Fundic gland polyps and association with proton pump inhibitor intake: a prospective study in 1,780 endoscopies. Dig Dis Sci 2011; 56:1743–1748.
Huang CZ, Lai RX, Mai L, Zhou HL, Chen HJ, Guo HX. Relative risk factors associated with the development of fundic gland polyps. Eur J Gastroenterol Hepatol 2014; 26:1217–1221.
Loffeld RJLF; Department of Internal Medicine and Gastroenterology, Zaans Medisch Centrum, Zaandam, The Netherlands. Presence of fundic gland polyps in patients undergoing upper gastrointestinal endoscopy: incidence and the relation with the use of proton pump inhibitors. J Clini Gastroenterol Treat 2017; 3:048.
Lee PL, Chen JJ, Wang SJ, Tung HD, Cheng CT, Lu NM. Fundic gland polyps is more common in patients with relative healthy gastric mucosa. Adv Dig Med 2018; 5:44–49.
Gao W, Huang YS, Lu SM, Li CY. The clinicopathological characteristics of gastric polyps and the relationship between fundic gland polyps, Helicobacter pylori infection, and proton pump inhibitors. Ann Palliat Med 2021; 10:2108–2114.
Declich P, Ambrosiani L, Grassini R, Tavani E, Bellone S, Bortoli A, et al. Fundic gland polyps: a still elusive entity on the eve of the year 2000. Pol J Pathol 2000; 51:3–8.
Klinkenberg-Knol EC, Nelis F, Dent J, Snel P, Mitchell B, Prichard P, et al. Long term omeprazole treatment in resistant gastroesophageal reflux disease. Efficacy, safety, and influence on gastric mucosa. Gastroenterology 2000; 118:661–669.
Vieth M, Stolte M. Fundic gland polyps are not induced by proton pump inhibitor therapy. Am J Clin Pathol 2001; 116:716–720.
Declich P, Tavani E, Ferrara A, Caruso S, Bellone S. Sporadic fundic gland polyps: clinico-pathologic features and associated diseases. Pol J Pathol 2005; 56:131–137.
Lundell Galmiche J-P, Hatlebakk J, Lind T, Junghard O; on behalf of the LOTUS trial collaborators. Comparing laparoscopic antireflux surgery with esomeprazole in the management of patients with chronic gastro-oesophageal reflux disease: a 3-year interim analysis of the LOTUS trial. Gut 2008; 57:1207–1213.
Fiocca R, Mastracci L, Attwood SE, Ell C, Galmiche J-P, Hatlebakk J, et al. Gastric exocrine and endocrine cell morphology under prolonged acid inhibition therapy: results of a 5-year follow-up in the LOTUS trial. Aliment Pharmacol Ther 2012; 36:959–971.
Cao HL, Qu R, Zhang ZH, Kong XY, Wang S, Jiang K, et al. Sporadic fundic gland polyps are not associated with proton pump inhibitors therapy but negatively correlate with Helicobacter pylori infection in China. Chin Med J (Engl) 2014; 127:1239–1243.
Camilo SM, Almeida EC, Miranzi BA, Silva JC, Nomelini RS, Etchebehere RM. Endoscopic and histopathologic gastric changes in chronic users of proton-pump inhibitors. Arq Gastroenterol 2015; 52:59–64.
de Farias Brito HL, Barros C, Freire MV, Silva Filho MND, Nascimento TV. Gastric fundic gland polyps: can histology be useful to predict proton pump inhibitors use? Arq Gastroenterol 2018; 55:380–384.
Jeong CY, Kim N, Lee HS, Yoon H, Shin CM, Park YS, et al. Risk factors of multiple gastric polyps according to the histologic classification: retrospective observational cohort study. Korean J Gastroenterol 2019; 74:17–29.
Velazquez-Dohorn M, López-Durand CF, Candanedo-González F, Araujo-Villalvazo EA, Gamboa-Domínguez A. Case-control analysis of fundic gland polyps and proton-pump inhibitors. A pathologist’s perspective. Rev Gastroenterol Mex (Engl Ed) 2020; 85:42–47.
Tran-Duy A, Spaetgens B, Hoes AW, de Wit NJ, Stehouwer CD. Use of proton pump inhibitors and risks of fundic gland polyps and gastric cancer: systematic review and meta-analysis. Clin Gastroenterol Hepatol 2016; 14:1706–1719.e5.
Martin FC, Chenevix-Trench G, Yeomans ND. Systematic review with meta-analysis: fundic gland polyps and proton pump inhibitors. Aliment Pharmacol Ther 2016; 44:915–925.
Suzuki E, Mitsuhashi T, Tsuda T, Yamamoto E. A typology of four notions of confounding in epidemiology. J Epidemiol 2017; 27:49–55.
Bours MJL. A nontechnical explanation of the counterfactual definition of confounding. J Clin Epidemiol 2020; 121:91–100.
Greco T, Zangrillo A, Biondi-Zoccai G, Landoni G. Meta-analysis: pitfalls and hints. Heart Lung Vessel 2013; 5:219–225.
Borenstein M, Hedges LV, Higgins JPT, Rothstein HR. Criticisms of meta-analysis. Introduction to meta-analysis. John Wiley & Sons Ltd; 2009. ISBN: 978-0-470-05724-7.
Dickey W, Kenny BD, McConnell JB. Prevalence of fundic gland polyps in a western European population. J Clin Gastroenterol 1996; 23:73–75.
Sonnenberg A, Genta RM. Prevalence of benign gastric polyps in a large pathology database. Dig Liver Dis 2015; 47:164–169.
Marcial MA, Villafana M, Hernandez-Denton J, Colon-Pagan JR. Fundic gland polyps: prevalence and clinicopathologic features. Am J Gastroenterol 1993; 88:1711–1713.
Shand AG, Taylor AC, Banerjee M, Lessels A, Coia J, Clark C, et al. Gastric fundic gland polyps in south-east Scotland: absence of adenomatous polyposis coli gene mutations and a strikingly low prevalence of Helicobacter pylori infection. J Gastroenterol Hepatol 2002; 17:1161–1164.
Levy MD, Bhattacharya B. Sporadic fundic gland polyps with low-grade dysplasia: a large case series evaluating pathologic and immunohistochemical findings and clinical behavior. Am J Clin Pathol 2015; 144:592–600.
Tosetti C, Nanni I. Use of proton pump inhibitors in general practice. World J Gastrointest Pharmacol Ther 2017; 8:180–185.
Genta RM, Schuler CM, Robiou CI, Lash RH. No association between gastric fundic gland polyps and gastrointestinal neoplasia in a study of over 100 000 patients. Clin Gastroenterol Hepatol 2009; 7:849–854.
Garcia-Alonso FJ, Martin-Mateos RM, Gonzalez-Martin JA, Foruny JR, Vazquez-Sequeiros E, de Miquel DB. Gastric polyps: analysis of endoscopic and histological features in our center. Rev Esp Enferm Dig 2011; 103:1130–0108.
Kroupa R, Pavlik T, Konecny S, Packova B, Dastych M, Pavlovsky Z, et al. The association between duration of and indications for proton pump inhibitor use and risk of gastric polyps. Eur J Gastroenterol Hepatol 2023; 35:829–835.
Moayyedi P, Eikelboom JW, Jackie Bosch J, Connolly SJ, Dyal L, Shestakovska O, et al. Safety of proton pump inhibitors based on a large, multi-year, randomized trial of patients receiving rivaroxaban or aspirin. Gastroenterology 2019; 157:682–691.
Hvid-Jensen F, Nielsen RB, Pedersen L, Funch-Jensen P, Drewes AM, Larsen FB, et al. Lifestyle factors among proton pump inhibitor users and nonusers: a cross-sectional study in a population-based setting. Clin Epidemiol 2013; 5:493–499.
Euser AM, Zoccali C, Jager KJ, Dekker FW. Cohort studies: prospective versus retrospective. Nephron Clin Pract 2009; 113:c214–c217.
Hammoudeh S, Gadelhaq W, Janahi I. Prospective cohort studies in medical research. In: Barría RM, editor. Cohort studies in health sciences. IntechOpen; 2018. https://www.intechopen.com/chapters/60939.
Ukai T, Shikata S, Nakayama T, Takemura YC. A comparison of the results of prospective and retrospective cohort studies in the field of digestive surgery. Surg Today 2017; 47:789–794.
Ahlbom A. Modern Epidemiology, 4th edition. TL Lash, TJ VanderWeele, S Haneuse, KJ Rothman. Wolters Kluwer, 2021. Eur J Epidemiol ; 36:767–768.
Austin PC, Xin Yu AY, Vyas MV, Kapral MK. Applying propensity score methods in clinical research in neurology. Neurology 2021; 97:856–863.
Kane LT, Fang T, Galetta MS, Goyal DKC, Nicholson KJ, Kepler CK, et al. Propensity score matching: a statistical method. Clin Spine Surg 2020; 33:120–122.
Ramsey DSL, Forsyth DM, Wright E, McKay M, Westbrooke I. Using propensity scores for causal inference in ecology: options, considerations, and a case study. Methods Ecol Evol 2019; 10:320–331.
Ho DE, Kosuke I, King G, Stuart EA. Matching as nonparametric preprocessing for reducing model dependence in parametric causal inference. Political Anal 2007; 15:199–236.
Khalaf M, Brock AS, Castell D. Sporadic fundic gland polyps and gastric acid suppression level. Am J Med Sci 2017; 354:561–564.
Fukuda M, Ishigaki H, Ban H, Sugimoto M, Tanaka E, Yonemaru J, et al. No transformation of a fundic gland polyp with dysplasia into invasive carcinoma after 14 years of follow-up in a proton pump inhibitor-treated patient: a case report. Pathol Int 2018; 68:706–711.
Kawase R, Nagata S, Onoyama M, Nakayama N, Honda Y, Kuwahara K, et al. A case of gastric adenocarcinoma arising from a fundic gland polyp. Clin J Gastroenterol 2009; 2:279–283.
Togo K, Ueo T, Yonemasu H, Honda H, Ishida T, Tanabe H, et al. Two cases of adenocarcinoma occurring in sporadic fundic gland polyps observed by magnifying endoscopy with narrow band imaging. World J Gastroenterol 2016; 22:9028–9034.
Jeong YS, Kim SE, Kwon MJ, Seo JY, Lim H, Park JW, et al. Signet-ring cell carcinoma arising from a fundic gland polyp in the stomach. World J Gastroenterol 2014; 20:18044–18047.
Shibukawa N, Wakahara Y, Ouchi S, Wakamatsu S, Kaneko A. Synchronous three gastric fundic gland polyps with low-grade dysplasia treated with endoscopic mucosal resection after being diagnosed to be tubular adenocarcinoma based on a biopsy specimen. Intern Med 2019; 58:1871–1875.
Nawata Y, Ichihara S, Hirasawa D, Tanaka I, Unno S, Igarashi K, et al. A case of gastric adenocarcinoma considered to originate from a sporadic fundic gland polyp in a Helicobacter pylori uninfected stomach. Clin J Gastroenterol 2020; 13:740–745.
Burt RW. Gastric fundic gland polyps. Gastroenterology 2003; 125:1462–1469.
Shaib YH, Rugge M, Graham DY, Genta RM. Management of gastric polyps: an endoscopy-based approach. Clin Gastroenterol Hepatol 2013; 11:1374–1384.
Mahachai V, Graham DY, Odze RD. Gastric polyps. ©2021 UpToDate. StatPearls Publishing; 2021. https://www.uptodate.com/contents/gastric-polyps/print. [Accessed 2021]
Islam RS, Patel NC, Lam-Himlin D, Nguyen CC. Gastric polyps: a review of clinical, endoscopic, and histopathologic features and management decisions. Gastroenterol Hepatol (N Y) 2013; 9:640–651.
Castro R, Pimentel-Nunes P, Dinis-Ribeiro M. Evaluation and management of gastric epithelial polyps. Best Pract Res Clin Gastroenterol 2017; 31:381–387.
Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. PLoS Med 2021; 18:e1003583.
Cochran WG. The combination of estimates from different experiments. Biometrics 1954; 10:101–129.
Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002; 21:1539–1558.
Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315:629–634.
Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika 1983; 70:41–55.
Desai RJ, Franklin JM. Alternative approaches for confounding adjustment in observational studies using weighting based on the propensity score: a primer for practitioners BMJ. BMJ (Clinical research ed.) 2019; 367:l5657.
Pishgar F, Greifer N, Leyrat C, Stuart E. MatchThem: matching and weighting multiply imputed datasets. MatchThem package in R 2022; version 4.4.1; 13:228.
Ho D, Imai K, King G, Stuart E. MatchIt: nonparametric preprocessing for parametric causal inference. J Stat Softw 2011; 42:1–28.
Austin PC. Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Stat Med 2009; 28:3083–3107.
Austin PC. Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies. Pharm Stat 2011; 10:150–161.
Greifer N; R Core Team. Colbalt: covariate balance tables and plots. R: A language and environment for statistical computing 2022; version 4.4.1.
Sekhon JS; R Core Team. Matching: multivariate and propensity score matching software for causal inference. R: a language and environment for statistical computing 2011; version 4.2.0. R Foundation for Statistical Computing Vienna Austria. https://www.R-project.org.
Rubin DB. Using propensity scores to help design observational studies: application to the tobacco litigation. Health Serv Outcomes Res Methodol 2001; 2:169–188.
Kolmogorov–Smirnov Test. The concise encyclopedia of statistics. Springer; 2008. doi: 10.1007/978-0-387-32833-1_214.
Stuart EA, Lee BK, Leacy FP. Prognostic score based balance measures can be a useful diagnostic for propensity score methods in comparative effectiveness research. J Clin Epidemiol 2013; 66:S84–S90.e1.
Hansen BB. The prognostic analogue of the propensity score. Biometrika 2008; 95:481–488.
Peura DA, Metz DC, Dabholkar AH, Paris MM, Yu P, Atkinson SN. Safety profile of dexlansoprazole MR, a proton pump inhibitor with a novel dual delayed release formulation: global clinical trial experience. Aliment Pharmacol Ther 2009; 30:1010–1021.
Shinozaki S, Osawa H, Hayashi Y, Sakamoto H, Miura Y, Lefor AK, et al. Changes in gastric morphology during long-term use of vonoprazan compared to proton pump inhibitors. Singapore Med J 2022; 63:283–287.
Harrer M, Cuijpers P, Furukawa TA, Ebert DD. Doing meta-analysis with R: a hands-on guide. Chapmann & Hall/CRC Press; 2021. ISBN 978-0-367-61007-4.
Borenstein M, Hedges LV, Higgins JPT, Rothstein HR. Introduction to meta-analysis. John Wiley & Sons, Ltd; 2009. ISBN:978-0-470-05724-7.
Deeks JJ, Higgins JPT, Altman DG [editors]. Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editors. Cochrane Handbook for systematic reviews of interventions version 6.3. Cochrane; 2022. www.training.cochrane.org/handbook.
van Buuren S, Groothuis-Oudshoorn K. Mice: multivariate imputation by chained equations in R. J Stat Soft 2011; 45:1–67. https://www.jstatsoft.org/v45/i03/.
Borenstein M, Hedges LV, Higgins JPT, Rothstein HR. Introduction to meta-analysis. John Wiley & Sons, Ltd; 2009.
Achana FA, Cooper NJ, Bujkiewicz S, Hubbard SJ, Kendrick D, Jones DR, et al. Network meta-analysis of multiple outcome measures accounting for borrowing of information across outcomes. BMC Med Res Methodol 2014; 14:92.
Sedgwick P. Meta-analyses: what is heterogeneity? BMJ 2015; 350:h1435.
Sainani KL. Propensity scores: uses and limitations. PM R 2012; 4:693–697.
Shiba K, Kawahara T. Using propensity scores for causal inference: pitfalls and tips. J Epidemiol 2021; 31:457–463.
Morgan CJ. Reducing bias using propensity score matching. J Nucl Cardiol 2018; 25:404–406.
Moulis G, Lapeyre-Mestre M. Propensity score: interests, use and limitations. A practical guide for clinicians. Rev Med Interne 2018; 39:805–812.
Cepeda MS, Boston R, Farrar JT, Strom BL. Comparison of logistic regression versus propensity score when the number of events is low and there are multiple confounders. Am J Epidemiol 2003; 158:280–287.
Takahari K, Haruma K, Ohtani H, Kiyoto S, Watanabe A, Kamada T, et al. Proton pump inhibitor induction of gastric cobblestone-like lesions in the stomach. Intern Med 2017; 56:2699–2703.
Leone PJ, Mankaney G, Sarvapelli S, Abushamma S, Lopez R, Cruise M, et al. Endoscopic and histologic features associated with gastric cancer in familial adenomatous polyposis. Gastrointest Endos 2019; 89:961–968.
Tacheci I, Repak R, Benesova L, Cyrany J, Bures J, Kohoutova D. Gastric adenocarcinoma and proximal polyposis of the stomach (GAPPS) – A Helicobacter-opposite point. Best Pract Res Clin Gastroenterol 2021; 50–51:101728.
Goto C, Okimoto K, Matsusaka K, Matsumura T, Akizue N, Ohta Y, et al. Long-term vonoprazan administration causes gastric fundic gland-type hyperplastic polyps and chronic bleeding. Clin J Gastroenterol 2023; 16:159–163.
Mizuno H, Yamada K, Minouchi K, Kamiyamamoto S, Hinoue Y. Efficacy of vonoprazan for 24-week maintenance therapy of patients with healed reflux esophagitis refractory to proton pump inhibitors. Biomed Rep. 2018; 8:148–155.
Mizuno H, Nishino M, Yamada K, Kamiyamamoto S, Hinoue Y. Efficacy of vonoprazan for 48-week maintenance therapy of patients with healed reflux esophagitis. Digestion 2020; 101:411–421.
Fossmark R, Jianu CS, Martinsen TC, Qvigstad G, Syversen U, Waldum HL. Serum gastrin and chromogranin A levels in patients with fundic gland polyps caused by long-term proton-pump inhibition. Scand J Gastroenterol 2008; 43:20–24.
Sakurai Y, Mori Y, Okamoto H, Nishimura A, Komura E, Araki T, et al. Acid-inhibitory effect of vonoprazan 20 mg compared with esomeprazole 20 mg or rabeprazole 10 mg in healthy adult male subjects - a randomised open-label crossover study. Aliment Pharmacol Ther 2015; 42:719–730.
Ashida K, Iwakiri K, Hiramatsu N, Sakurai Y, Hori T, Kudou K, et al. Maintenance for healed erosive esophagitis: phase III comparison of vonoprazan with lansoprazole. World J Gastroenterol 2018; 24:1550–1561.
Driman DK, Wright C, Tougas G, Riddell RH. Omeprazole produces parietal cell hypertrophy and hyperplasia in humans. Dig Dis Sci 1996; 41:2039–2047.
Pregun I, Herszényi L, Juhász M, Miheller P, Hritz I, Patócs A, et al. Effect of proton-pump inhibitor therapy on serum chromogranin a level. Digestion 2011; 84:22–28.
Straub SF, Drage MG, Gonzalez RS. Comparison of dysplastic fundic gland polyps in patients with and without familial adenomatous polyposis. Histopathology 2018; 72:1172–1179.
Lloyd IE, Kohlmann WK, Gligorich K, Hall A, Lyon E, Downs-Kelly E, et al. A clinicopathologic evaluation of incidental fundic gland polyps with dysplasia: implications for clinical management. Am J Gastroenterol 2017; 112:1094–1102.
Jalving M, Koornstra JJ, Götz JM, van der Waaij LA, de Jong S, Zwart N, et al. High-grade dysplasia in sporadic fundic gland polyps: a case report and review of the literature. Eur J Gastroenterol Hepatol 2003; 15:1229–1233.
Tazaki S, Nozu F, Yosikawa N, Imawari M, Suzuki N, Tominaga K, et al. Sporadic fundic gland polyp-related adenomas occurred in non-atrophic gastric mucosa without helicobacter pylori infection. Dig Endosc 2011; 23:182–186.
Varghese S, Le V, Ali T. Large fundic gland polyps in the stomach. Gastroenterol Hepatol (N Y) 2016; 12:153–154.
Yamaguchi T, Ishida H, Ueno H, Kobayashi H, Hinoi T, Inoue Y, et al. Upper gastrointestinal tumours in Japanese familial adenomatous polyposis patients. Jpn J Clin Oncol 2016; 46:310–315.
Nakamura K, Nonaka S, Nakajima T, Yachida T, Abe S, Sakamoto T, et al. Clinical outcomes of gastric polyps and neoplasms in patients with familial adenomatous polyposis. Endosc Int Open 2017; 05:E137–E145.
Stolte M, Bethke B, Seifert E, Armbrecht U, Lütke A, Goldbrunner P, et al. Observation of gastric glandular cysts in the corpus mucosa of the stomach under omeprazole treatment. Z Gastroenterol 1995; 33:146–149.
Wu TT, Kornacki S, Rashid A, Yardley JH, Hamilton SR. Dysplasia and dysregulation of proliferation in foveolar and surface epithelia of fundic gland polyps from patients with familial adenomatous polyposis. Am J Surg Pathol 1998; 22:293–298.
Abraham SC, Nobukawa B, Giardiello FM, Hamilton SR, Wu TT. Fundic gland polyps in familial adenomatous polyposis: neoplasms with frequent somatic adenomatous polyposis coli gene alterations. Am J Pathol 2000; 157:747–754.
Arnason T, Liang W-Y, Alfaro E, Kelly P, Chung DC, Odze RD, et al. Morphology and natural history of familial adenomatous polyposis-associated dysplastic fundic gland polyps. Histopathology 2014; 65:353–362.
Nonaka S, Hashimoto T, Oda I, Sekine S. Sporadic pyloric gland adenoma associated with a large fundic gland polyp: genetic evidence for stepwise progression. Gastric Cancer 2020; 23:1102–1106.
Nakano K, Kawachi H, Chino A, Kita M, Arai M, Ide D, et al. Phenotypic variations of gastric neoplasms in familial adenomatous polyposis are associated with endoscopic status of atrophic gastritis. Dig Endosc 2020; 32:547–556.
Foretová L, Navrátilová M, Svoboda M, Grell P, Nemec L, Sirotek L, et al. GAPPS - gastric adenocarcinoma and proximal polyposis of the stomach syndrome in 8 families tested at Masaryk Memorial Cancer Institute - Prevention and Prophylactic Gastrectomies. Klin Onkol 2019; 32 (Suppl 2):109–117.
Lerner BA, Llor X. Genetic gastric cancer risk syndromes. Curr Treat Options Gastroenterol. 2020; 18:604–615.
Fukuda M, Ishigaki H, Sugimoto M, Mukaisho K-I, Matsubara A, Ishida H, et al. Histological analysis of fundic gland polyps secondary to PPI therapy. Histopathology 2019; 75:537–545.
Jalving M, Koornstra JJ, Boersma-van Ek W, de Jong S, Karrenbeld A, Hollema H, et al. Dysplasia in fundic gland polyps is associated with nuclear beta-catenin expression and relatively high cell turnover rates. Scand J Gastroenterol 2003; 38:916–922.
Chiurillo MA. Role of the Wnt/β-catenin pathway in gastric cancer: an in-depth literature review. World J Exp Med 2015; 5:84–102.
Cao HL, Song SL, Yang BL, Zhang ZH, Zhang H, Qu R, et al. Typical endoscopic appearance accurately predicts sporadic fundic gland polyps: a retrospective study of 47 771 endoscopies. Chin Med J (Engl) 2013; 126:2984–2986.
Goddard AF, Badreldin R, Pritchard M, walker MM, Warren B; on behalf of British Society of Gastroenterology. The management of gastric polyps. Gut 2010; 59:1270–1276.
Pouw RE, Bredenoord AJ. Mistakes in the use of PPIs and how to avoid them (Mistake 6. Stopping a PPI because of fundic gland polyposis). United Euro Gastroenterol J 2017; 17:15–17.